Anti-Siglec-15 antibody
AssigneeDaiichi Sankyo Company, Limited
InventorsYoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
Life of this patent
Estimating the term…
Abstract
Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
Claims10
A pharmaceutical composition comprising an antibody or antigen binding fragment thereof in an amount effective to inhibit osteoclast differentiation, wherein the antibody or antigen binding fragment comprises:
- a light chain sequence that comprises a light chain variable region having CDRL1, CDRL2, and CDRL3, wherein CDRL1, comprises the amino acid sequence of SEQ ID NO:
- 47, CDRL2, comprises the amino acid sequence of SEQ ID NO:
- 48, and CDRL3, comprises the amino acid sequence of SEQ ID NO:
- 49, and a heavy chain sequence that comprises a heavy chain variable region having CDRH1, CDRH2, and CDRH3, wherein CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 44, CDRH2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO:
- 45 and SEQ ID NO:
- 97, and CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 46, wherein the antibody or antigen binding fragment thereof binds a Siglec-15 protein comprising the amino acid sequence of SEQ ID NO:
- 2 or 4, and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.